Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 45
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection

  • Lodi, Sara
  • Fisher, Martin
  • Phillips, Andrew
  • De Luca, Andrea
  • Ghosn, Jade
  • Malyuta, Ruslan
  • Zangerle, Robert
  • Moreno, Santiago
  • Vanhems, Philippe
  • Boufassa, Faroudy
  • Guiguet, Marguerite
  • Porter, Kholoud
BACKGROUND: The risk/benefit of initiating ART in primary HIV infection (PHI) is unclear. The benefits are more likely to outweigh the risks in patients with severe PHI. An accepted definition of severe PHI is, however, lacking. METHODS: CASCADE patients with HIV test interval <6 months were classified as severe and non-severe PHI based on whether the following traits were recorded in the first 6 months following seroconversion: severe specific pre-defined symptoms, central nervous system-implicated illness, and ≥1, ≥2 CD4<350 (and <500) cells/mm(3). For each definition, we used Kaplan-Meier curves and Cox survival models to compare time to AIDS/death, censoring at the earlier of last clinic visit or 1/1/1997, when combination antiretroviral therapy (cART) became available. RESULTS: Among 1108 included patients mostly males (85%) infected through sex between men (71%), 366 were diagnosed with AIDS/died. The risk of AIDS/death was significantly higher for individuals with severe symptoms, those with ≥1 CD4<350 cells/mm(3) or ≥2 CD4 <500 cells/mm(3) in the first 6 months [aHR (95% confidence interval) 2.1 (1.4,3.2), 2.0 (1.5,2.7), and 2.3, (1.5-3.5) respectively]. Median [interquantile range] survival for patients with ≥2, ≥1 and no CD4<350 cells/mm(3) within 6 months of seroconversion was 3.9 [2.7,6.5], 5.4 [4.5,8.4] and 8.1 [4.3,10.3] years, respectively. The diagnosis of CNS-implicated symptoms was rare and did not appear to be prognostic. CONCLUSION: One CD4 count <350 or two <500 cells/mm(3) within 6 months of seroconversion and/or severe illness in PHI may be useful early indicators of individuals at high risk of disease progression.
Repisalud
Publicación Artículo científico (JournalArticle)

Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings

  • Trickey, Adam
  • van Sighem, Ard
  • Stover, John
  • Abgrall, Sophie
  • Grabar, Sophie
  • Bonnet, Fabrice
  • Berenguer, Juan
  • Wyen, Christoph
  • Casabona, Jordi
  • d'Arminio Monforte, Antonella
  • Cavassini, Matthias
  • Amo, Julia del
  • Zangerle, Robert
  • Gill, M John
  • Obel, Niels
  • Sterne, Jonathan A C
  • May, Margaret T
Introduction: HIV cohort data from high-income European countries were compared with the UNAIDS Spectrum modelling parameters for these same countries to validate mortality rates and excess mortality estimates for people living with HIV (PLHIV) on antiretroviral therapy (ART). Methods: Data from 2000 to 2015 were analysed from the Antiretroviral Therapy Cohort Collaboration (ART-CC) for Austria, Denmark, France, Italy, the Netherlands, Spain, and Switzerland. Flexible parametric models were used to compare all-cause mortality rates in the ART-CC and Spectrum. The percentage of AIDS-related deaths and excess mortality (both are the same within Spectrum) were compared, with excess mortality defined as that in excess of the general population mortality. Results: Analyses included 94 026 PLHIV with 585 784 person-years of follow-up, from which there were 5515 deaths. All-cause annual mortality rates in Spectrum for 2000-2003 were 0.0121, reducing to 0.0078 in 2012-2015, whilst the ART-CC's corresponding annual mortality rates were 0.0151 [95% confidence interval (95% CI): 0.0130-0.0171] reducing to 0.0049 (95% CI: 0.0039-0.0060). The percentage of AIDS-related deaths in Spectrum was 74.7% in 2000-2003, dropping to 43.6% in 2012-2015. In the ART-CC, AIDS-related mortality constitutes 45.3% (95% CI: 38.4-52.9%) of mortality in 2000-2003 and 26.7% (95% CI: 19-46%) between 2012 and 2015. Excess mortality in the ART-CC was broadly similar to the Spectrum estimates, dropping from 75.3% (95% CI: 60.3-95.2%) in 2000-2003 to 30.7% (95% CI: 25.5-63.7%) in 2012-2015. Conclusion: All-cause mortality assumptions for PLHIV on ART in high-income European settings should be adjusted in Spectrum to be higher in 2000-2003 and decline more quickly to levels currently captured for recent years.
Repisalud
Publicación Artículo científico (JournalArticle)

Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death

  • Olson, Ashley D
  • Walker, A Sarah
  • Suthar, Amitabh B
  • Sabin, Caroline
  • Bucher, Heiner C
  • Jarrin Vera, Inmaculada
  • Moreno, Santiago
  • Pérez-Hoyos, Santiago
  • Porter, Kholoud
  • Ford, Deborah
  • CASCADE Collaboration in EuroCoord
BACKGROUND: Viremia copy-years (VCY), a time-updated measure of cumulative HIV exposure, predicts AIDS/death; although its utility in deciding when to start combination antiretroviral therapy (cART) remains unclear. We aimed to assess the impact of initiating versus deferring cART on risk of AIDS/death by levels of VCY both independent of and within CD4 cell count strata ≥500 cells per cubic millimeter. METHODS: Using Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) data, we created a series of nested "trials" corresponding to consecutive months for individuals ≥16 years at seroconversion after 1995 who were cART-naive and AIDS-free. Pooling across all trials, time to AIDS/death by CD4, and VCY strata was compared in those initiating vs. deferring cART using Cox models adjusted for: country, sex, risk group, seroconversion year, age, time since last HIV-RNA, and current CD4, VCY, HIV-RNA, and mean number of previous CD4/HIV-RNA measurements/year. RESULTS: Of 9353 individuals, 5312 (57%) initiated cART and 486 (5%) acquired AIDS/died. Pooling CD4 strata, risk of AIDS/death associated with initiating vs. deferring cART reduced as VCY increased. In patients with high CD4 cell counts, ≥500 cells per cubic millimeter, there was a trend for a greater reduction for those initiating vs. deferring with increasing VCY (P = 0.09), with the largest benefit in the VCY ≥100,000 copy-years/mL group [hazard ratio (95% CI) = 0.41 (0.19 to 0.87)]. CONCLUSIONS: For individuals with CD4 ≥500 cells per cubic millimeter, limiting the cumulative HIV burden to <100,000 copy-years/mL through cART may reduce the risk of AIDS/death.
Repisalud
Publicación Artículo científico (JournalArticle)

Evaluating the Impact of Functional Genetic Variation on HIV-1 Control

  • McLaren, Paul J
  • Pulit, Sara L
  • Gurdasani, Deepti
  • Bartha, Istvan
  • Shea, Patrick R
  • Pomilla, Cristina
  • Gupta, Namrata
  • Gkrania-Klotsas, Effrossyni
  • Young, Elizabeth H
  • Bannert, Norbert
  • Amo, Julia del
  • Gill, M John
  • Gilmour, Jill
  • Kellam, Paul
  • Kelleher, Anthony D
  • Sönnerborg, Anders
  • Wolinsky, Steven M
  • Zangerle, Robert
  • Post, Frank A
  • Fisher, Martin
  • Haas, David W
  • Walker, Bruce D
  • Porter, Kholoud
  • Goldstein, David B
  • Sandhu, Manjinder S
  • de Bakker, Paul I W
  • Fellay, Jacques
Background. Previous genetic association studies of human immunodeficiency virus-1 (HIV-1) progression have focused on common human genetic variation ascertained through genome-wide genotyping. Methods. We sought to systematically assess the full spectrum of functional variation in protein coding gene regions on HIV-1 progression through exome sequencing of 1327 individuals. Genetic variants were tested individually and in aggregate across genes and gene sets for an influence on HIV-1 viral load. Results. Multiple single variants within the major histocompatibility complex (MHC) region were observed to be strongly associated with HIV-1 outcome, consistent with the known impact of classical HLA alleles. However, no single variant or gene located outside of the MHC region was significantly associated with HIV progression. Set-based association testing focusing on genes identified as being essential for HIV replication in genome-wide small interfering RNA (siRNA) and clustered regularly interspaced short palindromic repeats (CRISPR) studies did not reveal any novel associations. Conclusions. These results suggest that exonic variants with large effect sizes are unlikely to have a major contribution to host control of HIV infection.
Repisalud
Publicación Artículo científico (JournalArticle)

Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?

  • Jarrin Vera, Inmaculada
  • Pantazis, Nikos
  • Dalmau, Judith
  • Phillips, Andrew N
  • Olson, Ashley
  • Mussini, Cristina
  • Boufassa, Faroudy
  • Costagliola, Dominique
  • Porter, Kholoud
  • Blanco, Juliá
  • Amo, Julia del
  • Martinez-Picado, Javier
  • CASCADE Collaboration in EuroCoord
Objective: This article compares trends in CD4þ T-cell recovery and proportions achieving optimal restoration ( 500 cells/ml) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. Methods: We included HIV-1 seroconverters achieving viral suppression within 6 months of cART. Rapid progressors were individuals experiencing at least one CD4þ less than 200 cells/ml within 12 months of seroconverters before cART. We used piecewise linear mixed models and logistic regression for optimal restoration. Results: Of 4024 individuals, 294 (7.3%) were classified as rapid progressors. At the same CD4þ T-cell count at cART start (baseline), rapid progressors experienced faster CD4þ T-cell increases than nonrapid progressors in first month [difference (95% confidence interval) in mean increase/month (square root scale): 1.82 (1.61; 2.04)], which reversed to slightly slower increases in months 1–18 [0.05 (0.06; 0.03)] and no significant differences in 18–60 months [0.003 (0.01; 0.01)]. Percentage achieving optimal restoration was significantly lower for rapid progressors than nonrapid progressors at months 12 (29.2 vs. 62.5%) and 36 (47.1 vs. 72.4%) but not at month 60 (70.4 vs. 71.8%). These differences disappeared after adjusting for baseline CD4þ T-cell count: odds ratio (95% confidence interval) 0.86 (0.61; 1.20), 0.90 (0.38; 2.17) and 1.56 (0.55; 4.46) at months 12, 36 and 60, respectively. Conclusion: Among people on suppressive antiretroviral therapy, rapid progressors experience faster initial increases of CD4þ T-cell counts than nonrapid progressors, but are less likely to achieve optimal restoration during the first 36 months after cART, mainly because of lower CD4þ T-cell counts at cART initiation.
Repisalud
Publicación Artículo científico (JournalArticle)

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study

  • May, Margaret T
  • Vehreschild, Jörg-Janne
  • Trickey, Adam
  • Obel, Niels
  • Reiss, Peter
  • Bonnet, Fabrice
  • Mary-Krause, Murielle
  • Samji, Hasina
  • Cavassini, Matthias
  • Gill, Michael John
  • Shepherd, Leah C
  • Crane, Heidi M
  • d'Arminio Monforte, Antonella
  • Burkholder, Greer A
  • Johnson, Margaret M
  • Sobrino-Vegas, Paz
  • Domingo, Pere
  • Zangerle, Robert
  • Justice, Amy C
  • Sterling, Timothy R
  • Miró, José María
  • Sterne, Jonathan A C
  • Antiretroviral Therapy Cohort Collaboration (ART-CC)
Background. CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized. Methods. We estimated mortality rates (MRs) by time since start of ART (<0.5, 0.5-0.9, 1-2.9, 3-4.9, 5-9.9, and ≥10 years) among patients from 18 European and North American cohorts who started ART during 1996-2001. Piecewise exponential models stratified by cohort were used to estimate crude and adjusted (for sex, age, transmission risk, period of starting ART [1996-1997, 1998-1999, 2000-2001], and AIDS and human immunodeficiency virus type 1 RNA at baseline) mortality rate ratios (MRRs) by CD4 count at start of ART (0-49, 50-99, 100-199, 200-349, 350-499, ≥500 cells/µL) overall and separately according to time since start of ART. Results. A total of 6344 of 37 496 patients died during 359 219 years of follow-up. The MR per 1000 person-years was 32.8 (95% confidence interval [CI], 30.2-35.5) during the first 6 months, declining to 16.0 (95% CI, 15.4-16.8) during 5-9.9 years and 14.2 (95% CI, 13.3-15.1) after 10 years' duration of ART. During the first year of ART, there was a strong inverse association of CD4 count at start of ART with mortality. This diminished over the next 4 years. The adjusted MRR per CD4 group was 0.97 (95% CI, .94-1.00; P = .054) and 1.02 (95% CI, .98-1.07; P = .32) among patients followed for 5-9.9 and ≥10 years, respectively. Conclusions. After surviving 5 years of ART, the mortality of patients who started ART with low baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 counts.
Repisalud
Publicación Artículo científico (JournalArticle)

Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.

  • Trickey, Adam
  • May, Margaret T
  • Gill, M John
  • Grabar, Sophie
  • Vehreschild, Janne
  • Wit, Ferdinand W N M
  • Bonnet, Fabrice
  • Cavassini, Matthias
  • Abgrall, Sophie
  • Berenguer, Juan
  • Wyen, Christoph
  • Reiss, Peter
  • Grabmeier-Pfistershammer, Katharina
  • Guest, Jodie L
  • Shepherd, Leah
  • Teira, Ramon
  • d'Arminio Monforte, Antonella
  • Amo, Julia del
  • Justice, Amy C
  • Costagliola, Dominique
  • Sterne, Jonathan A C
People living with HIV (PLHIV) are more likely than the general population to develop AIDS-defining malignancies (ADMs) and several non-ADMs (NADMs). Information is lacking on survival outcomes and cause-specific mortality after cancer diagnosis among PLHIV. We investigated causes of death within 5 years of cancer diagnosis in PLHIV enrolled in European and North American HIV cohorts starting antiretroviral therapy (ART) 1996-2015, aged ≥16 years, and subsequently diagnosed with cancer. Cancers were grouped: ADMs, viral NADMs and nonviral NADMs. We calculated cause-specific mortality rates (MR) after diagnosis of specific cancers and compared 5-year survival with the UK and France general populations. Among 83,856 PLHIV there were 4,436 cancer diagnoses. Of 603 deaths after ADM diagnosis, 292 (48%) were due to an ADM. There were 467/847 (55%) and 74/189 (39%) deaths that were due to an NADM after nonviral and viral NADM diagnoses, respectively. MR were higher for diagnoses between 1996 and 2005 versus 2006-2015: ADMs 102 (95% CI 92-113) per 1,000 years versus 88 (78-100), viral NADMs 134 (106-169) versus 111 (93-133) and nonviral NADMs 264 (232-300) versus 226 (206-248). Estimated 5-year survival for PLHIV diagnosed with liver (29% [19-39%]), lung (18% [13-23%]) and cervical (75% [63-84%]) cancer was similar to general populations. Survival after Hodgkin's lymphoma diagnosis was lower in PLHIV (75% [67-81%]). Among ART-treated PLHIV diagnosed with cancer, MR and causes of death varied by cancer type, with mortality highest for liver and lung cancers. Deaths within 5 years of NADM diagnoses were more likely to be from cancer than AIDS.
Repisalud
Publicación Artículo científico (JournalArticle)

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation

  • Pettit, April C
  • Giganti, Mark J
  • Ingle, Suzanne M
  • May, Margaret T
  • Shepherd, Bryan E
  • Gill, Michael J
  • Fätkenheuer, Gerd
  • Abgrall, Sophie
  • Saag, Michael S
  • Amo, Julia del
  • Justice, Amy C
  • Miró, José María
  • Cavassini, Matthias
  • Dabis, François
  • Monforte, Antonella D
  • Reiss, Peter
  • Guest, Jodie
  • Moore, David
  • Shepherd, Leah
  • Obel, Niels
  • Crane, Heidi M
  • Smith, Colette
  • Teira, Ramon
  • Zangerle, Robert
  • Sterne, Jonathan A C
  • Sterling, Timothy R
INTRODUCTION: HIV-1 infection leads to chronic inflammation and to an increased risk of non-AIDS mortality. Our objective was to determine whether AIDS-defining events (ADEs) were associated with increased overall and cause-specific non-AIDS related mortality after antiretroviral therapy (ART) initiation. METHODS: We included HIV treatment-naïve adults from the Antiretroviral Therapy Cohort Collaboration (ART-CC) who initiated ART from 1996 to 2014. Causes of death were assigned using the Coding Causes of Death in HIV (CoDe) protocol. The adjusted hazard ratio (aHR) for overall and cause-specific non-AIDS mortality among those with an ADE (all ADEs, tuberculosis (TB), Pneumocystis jiroveci pneumonia (PJP), and non-Hodgkin's lymphoma (NHL)) compared to those without an ADE was estimated using a marginal structural model. RESULTS: The adjusted hazard of overall non-AIDS mortality was higher among those with any ADE compared to those without any ADE (aHR 2.21, 95% confidence interval (CI) 2.00 to 2.43). The adjusted hazard of each of the cause-specific non-AIDS related deaths were higher among those with any ADE compared to those without, except metabolic deaths (malignancy aHR 2.59 (95% CI 2.13 to 3.14), accident/suicide/overdose aHR 1.37 (95% CI 1.05 to 1.79), cardiovascular aHR 1.95 (95% CI 1.54 to 2.48), infection aHR (95% CI 1.68 to 2.81), hepatic aHR 2.09 (95% CI 1.61 to 2.72), respiratory aHR 4.28 (95% CI 2.67 to 6.88), renal aHR 5.81 (95% CI 2.69 to 12.56) and central nervous aHR 1.53 (95% CI 1.18 to 5.44)). The risk of overall and cause-specific non-AIDS mortality differed depending on the specific ADE of interest (TB, PJP, NHL). CONCLUSIONS: In this large multi-centre cohort collaboration with standardized assignment of causes of death, non-AIDS mortality was twice as high among patients with an ADE compared to without an ADE. However, non-AIDS related mortality after an ADE depended on the ADE of interest. Although there may be unmeasured confounders, these findings suggest that a common pathway may be independently driving both ADEs and NADE mortality. While prevention of ADEs may reduce subsequent death due to NADEs following ART initiation, modification of risk factors for NADE mortality remains important after ADE survival.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

  • Peters, Lars
  • Mocroft, Amanda
  • Soriano, Vincent
  • Rockstroh, Jürgen Kurt
  • Rauch, Andri
  • Karlsson, Anders
  • Knysz, Brygida
  • Pradier, Christian
  • Zilmer, Kai
  • Lundgren, Jens D.
  • Gatell, José M.
  • Miró Meda, José M. (José María), 1956-
  • EuroSIDA Study Group
Background: Whereas it is well established that various soluble biomarkers can predict level of liver fibrosis, their ability to predict liver-related clinical outcomes is less clearly established, in particular among HIV/viral hepatitis co-infected persons. We investigated plasma hyaluronic acid's (HA) ability to predict risk of liver-related events (LRE; hepatic coma or liver-related death) in the EuroSIDA study. Methods: Patients included were positive for anti-HCV and/or HBsAg with at least one available plasma sample. The earliest collected plasma sample was tested for HA (normal range 0-75 ng/mL) and levels were associated with risk of LRE. Change in HA per year of follow-up was estimated after measuring HA levels in latest sample before the LRE for those experiencing this outcome (cases) and in a random selection of one sixth of the remaining patients (controls). Results: During a median of 8.2 years of follow-up, 84/1252 (6.7%) patients developed a LRE. Baseline median (IQR) HA in those without and with a LRE was 31.8 (17.2-62.6) and 221.6 ng/mL (74.9-611.3), respectively (p,0.0001). After adjustment, HA levels predicted risk of contracting a LRE; incidence rate ratios for HA levels 75-250 or $250 vs. ,75 ng/mL were 5.22 (95% CI 2.86-9.26, p,0.0007) and 28.22 (95% CI 14.95-46.00, p,0.0001), respectively. Median HA levels increased substantially prior to developing a LRE (107.6 ng/mL, IQR 0.8 to 251.1), but remained stable for controls (1.0 ng/mL, IQR -5.1 to 8.2), (p,0.0001 comparing cases and controls), and greater increases predicted risk of a LRE in adjusted models (p,0.001). Conclusions: An elevated level of plasma HA, particularly if the level further increases over time, substantially increases the risk of contracting LRE over the next five years. HA is an inexpensive, standardized and non-invasive supplement to other methods aimed at identifying HIV/viral hepatitis co-infected patients at risk of hepatic complications.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

CD4 cell count and the risk of AIDS or death in HIV infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE

  • Miró Meda, José M. (José María), 1956-
  • Noguera Julian, Antoni
  • Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
BACKGROUND: Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load. METHODS AND FINDINGS: Using data from the Collaboration of Observational HIV Epidemiological Research Europe (2010 merger), we assessed the risk of a new AIDS-defining event or death in successfully treated patients. We accumulated episodes of viral suppression for each patient while on cART, each episode beginning with the second of two consecutive plasma viral load measurements <50 copies/µl and ending with either a measurement >500 copies/µl, the first of two consecutive measurements between 50-500 copies/µl, cART interruption or administrative censoring. We used stratified multivariate Cox models to estimate the association between time updated CD4 cell count and a new AIDS event or death or death alone. 75,336 patients contributed 104,265 suppression episodes and were suppressed while on cART for a median 2.7 years. The mortality rate was 4.8 per 1,000 years of viral suppression. A higher CD4 cell count was always associated with a reduced risk of a new AIDS event or death; with a hazard ratio per 100 cells/µl (95% CI) of: 0.35 (0.30-0.40) for counts <200 cells/µl, 0.81 (0.71-0.92) for counts 200 to <350 cells/µl, 0.74 (0.66-0.83) for counts 350 to <500 cells/µl, and 0.96 (0.92-0.99) for counts ≥500 cells/µl. A higher CD4 cell count became even more beneficial over time for patients with CD4 cell counts <200 cells/µl. CONCLUSIONS: Despite the low mortality rate, the risk of a new AIDS event or death follows a CD4 cell count gradient in patients with viral suppression. A higher CD4 cell count was associated with the greatest benefit for patients with a CD4 cell count <200 cells/µl but still some slight benefit for those with a CD4 cell count ≥500 cells/µl.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.

  • Wyss, Natascha
  • Zwahlen, Marcel
  • Clifford, Gary
  • Campbell, Maria
  • Chakraborty, Rana
  • Bonnet, Fabrice
  • Chene, Geneviève
  • Bani-Sadr, Firouze
  • Verbon, Annelies
  • Zangerle, Robert
  • Paparizos, Vassilios
  • Prins, Maria
  • Dronda, Fernando
  • Le Moing, Vincent
  • Antinori, Andrea
  • Quiros Roldan, Eugenia
  • Mussini, Cristina
  • Miró Meda, José M. (José María), 1956-
  • Meyer, Laurence
  • Vehreschild, Jörg Janne
  • Obel, Niels
  • Mocroft, Amanda
  • Brockmeyer, Norbert H.
  • Boue, François
  • Sabin, Caroline
  • Spagnuolo, Vincenzo
  • Hasse, Barbara
  • Wit, Stéphane de
  • Roca, Bernardino
  • Egger, Matthias
  • Bohlius, Julia
BACKGROUND:  Kaposi sarcoma (KS) remains a frequent cancer in human immunodeficiency virus (HIV)-positive patients starting combination antiretroviral therapy (cART). We examined incidence rates and risk factors for developing KS in different periods after starting cART in patients from European observational HIV cohorts. METHODS:  We included HIV-positive adults starting cART after 1 January 1996. We analyzed incidence rates and risk factors for developing KS up to 90 and 180 days and 1, 2, 5, and 8 years after cART start and fitted univariable and multivariable Cox regression models. RESULTS:  We included 109 461 patients from 21 prospective clinical cohorts in Europe with 916 incident KS cases. The incidence rate per 100 000 person-years was highest 6 months after starting cART, at 953 (95% confidence interval, 866-1048), declining to 82 (68-100) after 5-8 years. In multivariable analyses adjusted for exposure group, origin, age, type of first-line regimen, and calendar year, low current CD4 cell counts increased the risk of developing KS throughout all observation periods after cART initiation. Lack of viral control was not associated with the hazard of developing KS in the first year after cART initiation, but was over time since starting cART increasingly positively associated (P < .001 for interaction). CONCLUSION:  In patients initiating cART, both incidence and risk factors for KS change with time since starting cART. Whereas soon after starting cART low CD4 cell count is the dominant risk factor, detectable HIV-1 RNA viral load becomes an increasingly important risk factor in patients who started cART several years earlier, independently of immunodeficiency.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Premature aging and immune senescence in HIV-infected children.

  • Gianesin, Ketty
  • Noguera Julian, Antoni
  • Zanchetta, Marisa
  • Del Bianco, Paola
  • Petrara, Maria Raffaella
  • Freguja, Riccardo
  • Rampon, Osvalda
  • Fortuny Guasch, Claudia
  • Camós Guijosa, Mireia
  • Mozzo, Elena
  • Giaquinto, Carlo
  • De Rossi, Anita
Objective: Several pieces of evidence indicate that HIV-infected adults undergo premature aging. The effect of HIV and antiretroviral therapy (ART) exposure on the aging process of HIV-infected children may be more deleterious since their immune system coevolves from birth with HIV. Design: Seventy-one HIV-infected (HIV+), 65 HIV-exposed-uninfected (HEU), and 56 HIV-unexposed-uninfected (HUU) children, all aged 0-5 years, were studied for biological aging and immune senescence. Methods: Telomere length and T-cell receptor rearrangement excision circle levels were quantified in peripheral blood cells by real-time PCR. CD4+ and CD8+ cells were analysed for differentiation, senescence, and activation/exhaustion markers by flow cytometry. Results: Telomere lengths were significantly shorter in HIV+ than in HEU and HUU children (overall, P < 0.001 adjusted for age); HIV+ ART-naive (42%) children had shorter telomere length compared with children on ART (P = 0.003 adjusted for age). T-cell receptor rearrangement excision circle levels and CD8+ recent thymic emigrant cells (CD45RA+CD31+) were significantly lower in the HIV+ than in control groups (overall, P = 0.025 and P = 0.005, respectively). Percentages of senescent (CD28−CD57+), activated (CD38+HLA-DR+), and exhausted (PD1+) CD8+ cells were significantly higher in HIV+ than in HEU and HUU children (P = 0.004, P < 0.001, and P < 0.001, respectively). Within the CD4+ cell subset, the percentage of senescent cells did not differ between HIV+ and controls, but programmed cell death receptor-1 expression was upregulated in the former. Conclusions: HIV-infected children exhibit premature biological aging with accelerated immune senescence, which particularly affects the CD8+ cell subset. HIV infection per se seems to influence the aging process, rather than exposure to ART for prophylaxis or treatment. Keywords: immune activation, immune senescence, microbial translocation, pediatric HIV/AIDS, premature aging, telomere length, T-cell receptor rearrangement excision circle
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

  • Pantazis, Nikos
  • Morrison, Charles
  • Amornkul, Pauli N.
  • Lewden,Charlotte
  • Salata, Robert A
  • Minga, Albert
  • Chipato, Tsungai
  • Jaffe, Harold
  • Lakhi, Shabir
  • Karita, Etienne
  • Porter, Kholoud
  • Meyer, Laurence
  • Touloumi, Giota
  • CASCADE Collaboration in EuroCoord
  • ANRS 1220 Primo-CI Study Group.
  • Gatell, José M.
Introduction: It is unknown whether HIV treatment guidelines, based on resource-rich country cohorts, are applicable to African populations. Methods: We estimated CD4 cell loss in ART-naïve, AIDS-free individuals using mixed models allowing for random intercept and slope, and time from seroconversion to clinical AIDS, death and antiretroviral therapy (ART) initiation by survival methods. Using CASCADE data from 20 European and 3 sub-Saharan African (SSA) cohorts of heterosexually-infected individuals, aged ≥15 years, infected ≥2000, we compared estimates between non-African Europeans, Africans in Europe, and Africans in SSA. Results: Of 1,959 (913 non-Africans, 302 Europeans - African origin, 744 SSA), two-thirds were female; median age at seroconversion was 31 years. Individuals in SSA progressed faster to clinical AIDS but not to death or non-TB AIDS. They also initiated ART later than Europeans and at lower CD4 cell counts. In adjusted models, Africans (especially from Europe) had lower CD4 counts at seroconversion and slower CD4 decline than non-African Europeans. Median (95% CI) CD4 count at seroconversion for a 15-29 year old woman was 607 (588-627) (non-African European), 469 (442-497) (European - African origin) and 570 (551-589) (SSA) cells/µL with respective CD4 decline during the first 4 years of 259 (228-289), 155 (110-200), and 199 (174-224) cells/µL (p<0.01). Discussion: Despite differences in CD4 cell count evolution, death and non-TB AIDS rates were similar across study groups. It is therefore prudent to apply current ART guidelines from resource-rich countries to African populations.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration.

  • Olson, Ashley D.
  • Meyer, Laurence
  • Prins, Maria
  • Thiebaut, Rodolphe
  • Gurdasani, Deepti
  • Guiguet, Marguerite
  • Chaix, Marie-Laure
  • Amornkul, Pauli N.
  • Babiker, Abdel
  • Sandhu, Manjinder S.
  • Porter, Kholoud
  • Gatell, José M.
BACKGROUND: Understanding the mechanisms underlying viral control is highly relevant to vaccine studies and elite control (EC) of HIV infection. Although numerous definitions of EC exist, it is not clear which, if any, best identify this rare phenotype. METHODS: We assessed a number of EC definitions used in the literature using CASCADE data of 25,692 HIV seroconverters. We estimated proportions maintaining EC of total ART-naïve follow-up time, and disease progression, comparing to non-EC. We also examined HIV-RNA and CD4 values and CD4 slope during EC and beyond (while ART naïve). RESULTS: Most definitions classify ∼ 1% as ECs with median HIV-RNA 43-903 copies/ml and median CD4>500 cells/mm(3). Beyond EC status, median HIV-RNA levels remained low, although often detectable, and CD4 values high but with strong evidence of decline for all definitions. Median % ART-naïve time as EC was ≥ 92% although overlap between definitions was low. EC definitions with consecutive HIV-RNA measurements <75 copies/ml with follow-up ≥ six months, or with 90% of measurements <400 copies/ml over ≥ 10 year follow-up preformed best overall. Individuals thus defined were less likely to progress to endpoint (hazard ratios ranged from 12.5-19.0 for non-ECs compared to ECs). CONCLUSIONS: ECs are rare, less likely to progress to clinical disease, but may eventually lose control. We suggest definitions requiring individuals to have consecutive undetectable HIV-RNA measurements for ≥ six months or otherwise with >90% of measurements <400 copies/ml over ≥ 10 years be used to define this phenotype.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study

  • Reekie, Joanne
  • Kowalska, Justyna D.
  • Karpov, Igor
  • Rockstroh, Jürgen Kurt
  • Karlsson, Anders
  • Rakhmanova, Aza
  • Horban, Andrzej
  • Kirk, Ole
  • Lundgren, Jens D.
  • Mocroft, Amanda
  • Gatell, José M.
  • Miró Meda, José M. (José María), 1956-
  • EuroSIDA Study Group
Background: Differences in access to care and treatment have been reported in Eastern Europe, a region with one of the fastest growing HIV epidemics, compared to the rest of Europe. This analysis aimed to establish whether there are regional differences in the mortality rate of HIV-positive individuals across Europe, and Argentina. Methods: 13,310 individuals under follow-up were included in the analysis. Poisson regression investigated factors associated with the risk of death. Findings: During 82,212 person years of follow-up (PYFU) 1,147 individuals died (mortality rate 14.0 per 1,000 PYFU (95% confidence interval [CI] 13.1-14.8). Significant differences between regions were seen in the rate of all-cause, AIDS and nonAIDS related mortality (global p,0.0001 for all three endpoints). Compared to South Europe, after adjusting for baseline demographics, laboratory measurements and treatment, a higher rate of AIDS related mortality was observed in East Europe (IRR 2.90, 95%CI 1.97-4.28, p,.0001), and a higher rate of non-AIDS related mortality in North Europe (IRR 1.51, 95%CI 1.24- 1.82, p,.0001). The differences observed in North Europe decreased over calendar-time, in 2009-2011, the higher rate of non-AIDS related mortality was no longer significantly different to South Europe (IRR 1.07, 95%CI 0.66-1.75, p = 0.77). However, in 2009-2011, there remained a higher rate of AIDS-related mortality (IRR 2.41, 95%CI 1.11-5.25, p = 0.02) in East Europe compared to South Europe in adjusted analysis. Interpretations: There are significant differences in the rate of all-cause mortality among HIV-positive individuals across different regions of Europe and Argentina. Individuals in Eastern Europe had an increased risk of mortality from AIDS related causes and individuals in North Europe had the highest rate of non-AIDS related mortality. These findings are important for understanding and reviewing HIV treatment strategies and policies across the European region.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Mortality according to CD4 count at start of combination antiretroviral therapy among HIV-infected patients followed for up to 15 years after start of treatment: collaborative cohort study

  • May, Margaret T.
  • Vehreschild, Jörg Janne
  • Trickey, Adam
  • Obel, Niels
  • Reiss, Peter
  • Bonnet, Fabrice
  • Mary-Krause, Murielle
  • Samji, Hasina
  • Cavassini, Matthias
  • Gill, Michael John
  • Shepherd, Leah C.
  • Crane, Heidi M.
  • D&apos;Arminio Monforte, Antonella
  • Burkholder, Greer A.
  • Johnson, Margaret M.
  • Sobrino Vegas, Paz
  • Domingo, Pere (Domingo Pedrol)
  • Zangerle, Robert
  • Justice, Amy C.
  • Sterling, Timothy R.
  • Miró Meda, José M. (José María), 1956-
  • Sterne, Jonathan A. C.
BACKGROUND: CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized. METHODS: We estimated mortality rates (MRs) by time since start of ART (<0.5, 0.5-0.9, 1-2.9, 3-4.9, 5-9.9, and ≥10 years) among patients from 18 European and North American cohorts who started ART during 1996-2001. Piecewise exponential models stratified by cohort were used to estimate crude and adjusted (for sex, age, transmission risk, period of starting ART [1996-1997, 1998-1999, 2000-2001], and AIDS and human immunodeficiency virus type 1 RNA at baseline) mortality rate ratios (MRRs) by CD4 count at start of ART (0-49, 50-99, 100-199, 200-349, 350-499, ≥500 cells/µL) overall and separately according to time since start of ART. RESULTS: A total of 6344 of 37 496 patients died during 359 219 years of follow-up. The MR per 1000 person-years was 32.8 (95% confidence interval [CI], 30.2-35.5) during the first 6 months, declining to 16.0 (95% CI, 15.4-16.8) during 5-9.9 years and 14.2 (95% CI, 13.3-15.1) after 10 years' duration of ART. During the first year of ART, there was a strong inverse association of CD4 count at start of ART with mortality. This diminished over the next 4 years. The adjusted MRR per CD4 group was 0.97 (95% CI, .94-1.00; P = .054) and 1.02 (95% CI, .98-1.07; P = .32) among patients followed for 5-9.9 and ≥10 years, respectively. CONCLUSIONS: After surviving 5 years of ART, the mortality of patients who started ART with low baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 counts.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation

  • Pettit, April C.
  • Giganti, Mark J.
  • Ingle, Suzanne M.
  • May, Margaret T.
  • Shepherd, Bryan E.
  • Gill, Michael John
  • Fätkenheuer, Gerd
  • Abgrall, Sophie
  • Saag, Michael S.
  • Amo Valero, Julia del
  • Justice, Amy C.
  • Miró Meda, José M. (José María), 1956-
  • Cavassini, Matthias
  • Dabis, François
  • Monforte, Antonella D.
  • Reiss, Peter
  • Guest, Jodie
  • Moore, David
  • Shepherd, Leah C.
  • Obel, Niels
  • Crane, Heidi M.
  • Smith, Colette J.
  • Zangerle, Robert
  • Sterne, Jonathan A. C.
  • Sterling, Timothy R.
  • Teira, Ramon
  • Antiretroviral Therapy Cohort Collaboration
Introduction:HIV-1 infection leads to chronic inflammation and to an increased risk of non-AIDS mortality. Our objective wasto determine whether AIDS-defining events (ADEs) were associated with increased overall and cause-specific non-AIDSrelated mortality after antiretroviral therapy (ART) initiation.Methods:We included HIV treatment-na ıve adults from the Antiretroviral Therapy Cohort Collaboration (ART-CC) who initi-ated ART from 1996 to 2014. Causes of death were assigned using the Coding Causes of Death in HIV (CoDe) protocol. Theadjusted hazard ratio (aHR) for overall and cause-specific non-AIDS mortality among those with an ADE (all ADEs, tuberculosis(TB),Pneumocystis jirovecipneumonia (PJP), and non-Hodgkin's lymphoma (NHL)) compared to those without an ADE was esti-mated using a marginal structural model.Results:The adjusted hazard of overall non-AIDS mortality was higher among those with any ADE compared to thosewithout any ADE (aHR 2.21, 95% confidence interval (CI) 2.00 to 2.43). The adjusted hazard of each of the cause-specificnon-AIDS related deaths were higher among those with anyADE compared to those without, except metabolic deaths(malignancy aHR 2.59 (95% CI 2.13 to 3.14), accident/suicide/overdose aHR 1.37(95% CI 1.05 to 1.79), cardiovascularaHR 1.95 (95% CI 1.54 to 2.48), infection aHR (95% CI 1.68 to 2.81), hepatic aHR 2.09 (95% CI 1.61 to 2.72), respira-tory aHR 4.28 (95% CI 2.67 to 6.88), renal aHR 5.81 (95% CI 2.69 to 12.56) and central nervous aHR 1.53 (95% CI 1.18to 5.44)). The risk of overall and cause-specific non-AIDS mortality differed depending onthe specific ADE of interest(TB, PJP, NHL).Conclusions:In this large multi-centre cohort collaboration with standardized assignment of causes of death, non-AIDS mor-tality was twice as high among patients with an ADE compared to without an ADE. However, non-AIDS related mortality afteran ADE depended on the ADE of interest. Although there may be unmeasured confounders, these findings suggest that acommon pathway may be independently driving both ADEs and NADE mortality. While prevention of ADEs may reduce subse-quent death due to NADEs following ART initiation, modification of risk factors for NADE mortality remains important afterADE survival.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

  • Mocroft, Amanda
  • Lundgren, Jens D.
  • Sabin, Miriam Lewis
  • Arminio Monforte, Antonella d&apos;
  • Brockmeyer, Norbert H.
  • Casabona, Jordi
  • Castagna, Antonella
  • Costagliola, Dominique
  • Dabis, François
  • De Wit, Stéphane
  • Fätkenheuer, Gerd
  • Furrer, Hansjakob
  • Johnson, Anne M.
  • Lazanas, Marios K.
  • Leport, Catherine
  • Moreno, Santiago
  • Obel, Niels
  • Post, Frank A.
  • Reekie, Joanne
  • Reiss, Peter
  • Sabin, Caroline
  • Skaletz Rorowski, Adriane
  • Suarez Lozano, Ignacio
  • Torti, Carlo
  • Warszawski, Josiane
  • Zangerle, Robert
  • Fabre Colin, Céline
  • Kjaer, Jesper
  • Chene, Geneviève
  • Grarup, Jesper
  • Kirk, Ole
  • Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
Background: Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. Methods and Findings: LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm3 or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). Conclusions: LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

  • Caro Vega, Yanink
  • Schultze, Anna
  • Efsen, Anne Marie W.
  • Post, Frank A.
  • Panteleev, Alexander
  • Skrahin, Aliaksandr
  • Miró Meda, José M. (José María), 1956-
  • Girardi, Enrico
  • Podlekareva, Daria N.
  • Lundgren, Jens D.
  • Sierra Madero, Juan
  • Toibaro, Javier
  • Andrade Villanueva, Jaime
  • Tetradov, Simona
  • Fehr, Jan
  • Caylà i Buqueras, Joan A.
  • Losso, Marcelo H.
  • Miller, Robert F.
  • Mocroft, Amanda
  • Kirk, Ole
  • Crabtree Ramírez, Brenda
Background: Efavirenz-based antiretroviral therapy (ART) regimens are preferred for treatment of adult HIV-positive patients co-infected with tuberculosis (HIV/TB). Few studies have compared outcomes among HIV/TB patients treated with efavirenz or non-efavirenz containing regimens. Methods: HIV-positive patients aged ≥16 years with a diagnosis of tuberculosis recruited to the TB:HIV study between Jan 1, 2011, and Dec 31, 2013 in 19 countries in Eastern Europe (EE), Western Europe (WE), and Latin America (LA) who received ART concomitantly with TB treatment were included. Patients either received efavirenz-containing ART starting between 15 days prior to, during, or within 90 days after starting tuberculosis treatment, (efavirenz group), or other ART regimens (non-efavirenz group). Patients who started ART more than 90 days after initiation of TB treatment, or who experienced ART interruption of more than 15 days during TB treatment were excluded. We describe rates and factors associated with death, virological suppression, and loss to follow up at 12 months using univariate, multivariate Cox, and marginal structural models to compare the two groups of patients. Results: Of 965 patients (647 receiving efavirenz-containing ART, and 318 a non-efavirenz regimen) 50% were from EE, 28% from WE, and 22% from LA. Among those not receiving efavirenz-containing ART, regimens mainly contained a ritonavir-boosted protease inhibitor (57%), or raltegravir (22%). At 12 months 1.4% of patients in WE had died, compared to 20% in EE: rates of virological suppression ranged from 21% in EE to 61% in WE. After adjusting for potential confounders, rates of death (adjusted Hazard Ratio; aHR, 95%CI: 1.13, 0.72-1.78), virological suppression (aHR, 95%CI: 0.97, 0.76-1.22), and loss to follow up (aHR, 95%CI: 1.17, 0.81-1.67), were similar in patients treated with efavirenz and non-efavirenz containing ART regimens. Conclusion: In this large, prospective cohort, the response to ART varied significantly across geographical regions, whereas the ART regimen (efavirenz or non-efavirenz containing) did not impact on the proportion of patients who were virologically-suppressed, lost to follow up or dead at 12 months.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

  • Zoufaly, Alexander
  • Cozzi-Lepri, Alessandro
  • Reekie, Joanne
  • Kirk, Ole
  • Lundgren, Jens D.
  • Reiss, Peter
  • Jevtovic, Djordje
  • Machala, Ladislav
  • Zangerle, Robert
  • Mocroft, Amanda
  • Van Lunzen, Jan 1963-
  • Miró Meda, José M. (José María), 1956-
  • Gatell, José M.
The impact of immunosuppression despite virological suppression (immuno-virological discordance, ID) on the risk of developing fatal and non-fatal AIDS/non-AIDS events is unclear and remains to be elucidated. METHODS: Patients in EuroSIDA starting at least 1 new antiretroviral drug with CD4<350 cells/µl and viral load (VL)>500 copies/mL were followed-up from the first day of VL< = 50 copies/ml until a new fatal/non-fatal non-AIDS/AIDS event. Considered non-AIDS events included non-AIDS malignancies, pancreatitis, severe liver disease with hepatic encephalopathy (>grade 3), cardio- and cerebrovascular events, and end-stage renal disease. Patients were classified over time according to whether current CD4 count was above (non-ID) or below (ID) baseline level. Relative rates (RR) of events were calculated for ID vs. non-ID using adjusted Poisson regression models. RESULTS: 2,913 patients contributed 11,491 person-years for the analysis of non-AIDS. 241 pre-specified non-AIDS events (including 84 deaths) and 89 AIDS events (including 10 deaths) occurred. The RR of developing pre-specified non-AIDS events for ID vs. non-ID was 1.96 (95% CI 1.37-2.81, p<0.001) in unadjusted analysis and 1.43 (0.94-2.17, p = 0.095) after controlling for current CD4 count. ID was not associated with the risk of AIDS events (aRR 0.76, 95% CI 0.41-1.38, p = 0.361). CONCLUSION: Compared to CD4 responders, patients with immuno-virological discordance may be at increased risk of developing non-AIDS events. Further studies are warranted to establish whether in patients with ID, strategies to directly modify CD4 count response may be needed besides the use of ART.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB: HIV study

  • Efsen, Anne Marie W.
  • Schultze, Anna
  • Miller, Robert F.
  • Panteleev, Alexander
  • Skrahin, Aliaksandr
  • Podlekareva, Daria N.
  • Miró Meda, José M. (José María), 1956-
  • Girardi, Enrico
  • Furrer, Hansjakob
  • Losso, Marcelo H.
  • Toibaro, Javier
  • Caylà i Buqueras, Joan A.
  • Mocroft, Amanda
  • Lundgren, Jens D.
  • Kirk, Ole
  • Post, Frank A.
  • Manzardo, Christian
  • Ligero, M. C.
  • González, J.
  • HIV study in EuroCoord
Objectives: Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods: In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART). Results: A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5-74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%. Conclusions: Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study

  • Judd, Ali
  • Chappell, Elizabeth
  • Turkova, Anna
  • Le Coeur, Sophie
  • Noguera Julian, Antoni
  • Goetghebuer, Tessa
  • Doerholt, Katja
  • Galli, Luisa
  • Pajkrt, Dasja
  • Marques, Laura
  • Collins, Intira J.
  • Gibb, Diana M.
  • González Tomé, Maria Isabel
  • Navarro, Marisa
  • Warszawski, Josiane
  • Königs, Christoph
  • Spoulou, Vana
  • Prata, Filipa
  • Chiappini, Elena
  • Naver, Lars
  • Giaquinto, Carlo
  • Thorne, Claire
  • Marczynska, Magdalena
  • Okhonskaia, Liubov
  • Posfay-Barbe, Klara
  • Ounchanum, Pradthana
  • Techakunakorn, Pornchai
  • Kiseleva, Galina
  • Malyuta, Ruslan
  • Volokha, Alla
  • Ene, Luminita
  • Goodall, Ruth
Background: Published estimates of mortality and progression to AIDS as children with HIV approach adulthood are limited. We describe rates and risk factors for death and AIDS-defining events in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17 middle- and high-income countries, including some in Western and Central Europe (W&CE), Eastern Europe (Russia and Ukraine), and Thailand. Methods and findings: Children with perinatal HIV aged <18 years initiating cART were followed until their 21st birthday, transfer to adult care, death, loss to follow-up, or last visit up until 31 December 2013. Rates of death and first AIDS-defining events were calculated. Baseline and time-updated risk factors for early/late (≤/>6 months of cART) death and progression to AIDS were assessed. Of 3,526 children included, 32% were from the United Kingdom or Ireland, 30% from elsewhere in W&CE, 18% from Russia or Ukraine, and 20% from Thailand. At cART initiation, median age was 5.2 (IQR 1.4-9.3) years; 35% of children aged <5 years had a CD4 lymphocyte percentage <15% in 1997-2003, which fell to 15% of children in 2011 onwards (p < 0.001). Similarly, 53% and 18% of children ≥5 years had a CD4 count <200 cells/mm3 in 1997-2003 and in 2011 onwards, respectively (p < 0.001). Median follow-up was 5.6 (2.9-8.7) years. Of 94 deaths and 237 first AIDS-defining events, 43 (46%) and 100 (42%) were within 6 months of initiating cART, respectively. Multivariable predictors of early death were: being in the first year of life; residence in Russia, Ukraine, or Thailand; AIDS at cART start; initiating cART on a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen; severe immune suppression; and low BMI-for-age z-score. Current severe immune suppression, low current BMI-for-age z-score, and current viral load >400 c/mL predicted late death. Predictors of early and late progression to AIDS were similar. Study limitations include incomplete recording of US Centers for Disease Control (CDC) disease stage B events and serious adverse events in some countries; events that were distributed over a long time period, and that we lacked power to analyse trends in patterns and causes of death over time. Conclusions: In our study, 3,526 children and adolescents with perinatal HIV infection initiated antiretroviral therapy (ART) in countries in Europe and Thailand. We observed that over 40% of deaths occurred ≤6 months after cART initiation. Greater early mortality risk in infants, as compared to older children, and in Russia, Ukraine, or Thailand as compared to W&CE, raises concern. Current severe immune suppression, being underweight, and unsuppressed viral load were associated with a higher risk of death at >6 months after initiation of cART.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers

  • Chereau, Fanny
  • Madec, Yoann
  • Sabin, Caroline
  • Obel, Niels
  • Ruiz-Mateos, Ezequiel
  • Chrysos, Georgios
  • Fidler, Sarah
  • Lehmann, Clara
  • Zangerle, Robert
  • Wittkop, Linda
  • Reiss, Peter
  • Hamouda, Osamah
  • Estrada Pérez, Vicente
  • Leal, Manuel
  • Mocroft, Amanda
  • García de Olalla, Patricia
  • Ammassari, Adriana
  • D'Arminio Monforte, Antonella
  • Mussini, Cristina
  • Segura, Ferrán
  • Castagna, Antonella
  • Cavassini, Matthias
  • Grabar, Sophie
  • Morlat, Philippe
  • De Wit, Stéphane
  • Lambotte, Olivier
  • Meyer, Laurence
[Objective] HIV controllers (HICs) spontaneously maintain HIV viral replication at low level without antiretroviral therapy (ART), a small number of whom will eventually lose this ability to control HIV viremia. The objective was to identify factors associated with loss of virological control., [Methods] HICs were identified in COHERE on the basis of ≥5 consecutive viral loads (VL) ≤500 copies/mL over ≥1 year whilst ART-naive, with the last VL ≤500 copies/mL measured ≥5 years after HIV diagnosis. Loss of virological control was defined as 2 consecutive VL >2000 copies/mL. Duration of HIV control was described using cumulative incidence method, considering loss of virological control, ART initiation and death during virological control as competing outcomes. Factors associated with loss of virological control were identified using Cox models. CD4 and CD8 dynamics were described using mixed-effect linear models., [Results] We identified 1067 HICs; 86 lost virological control, 293 initiated ART, and 13 died during virological control. Six years after confirmation of HIC status, the probability of losing virological control, initiating ART and dying were 13%, 37%, and 2%. Current lower CD4/CD8 ratio and a history of transient viral rebounds were associated with an increased risk of losing virological control. CD4 declined and CD8 increased before loss of virological control, and before viral rebounds., [Discussion] Expansion of CD8 and decline of CD4 during HIV control may result from repeated low-level viremia. Our findings suggest that in addition to superinfection, other mechanisms, such as low grade viral replication, can lead to loss of virological control in HICs., The COHERE study group has received unrestricted funding from: Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS), France; HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Denmark. The research leading to these results received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement n° 260694., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe

  • Thorne, Claire
  • Turkova, Anna
  • Indolfi, Giuseppe
  • Venturini, Elisabetta
  • Giaquinto, Carlo
  • Goetghebuer, Tessa
  • Hainaut, Marc
  • Van der Kelen, Evelyne
  • Königs, Christoph
  • Mantzsch, Kathleen
  • Baumann, Ulrich
  • de Martino, Maurizio
  • Galli, Luisa
  • Giacomet, Vania
  • Nicolini, Laura Ambra
  • Del Puente, Filippo
  • Gabiano, Clara
  • Guarino, Alfredo
  • Martinazzi, Silvia
  • Miniaci, Angela
  • Dobsz, Sabina
  • Marczynska, Magdalena
  • Ene, Luminita
  • Duiculescu, Dan
  • Miloenko, Milana
  • Dodonov, Konstantin
  • Latysheva, Inga
  • Voronin, Evgeny
  • Rojo, Pablo
  • Ramos, José Tomás
  • Navarro Gómez, María Luisa
  • Jiménez de Ory, Santiago
  • Sainz, Talia
  • Mellado, Maria Jose
  • García, Miluca
  • Pérez, Carlos
  • Moreno-Pérez, David
  • Nuñez, Esmeralda
  • Gracia García, Mercedes
  • Terol, Pedro
  • Neth, Olaf
  • Falcón Neyra, Lola
  • Otero, Carmen
  • Rincón, Elena
  • Gavilán, César
  • López, Carmen
  • Santos, Juan Luis
  • Couceiro, José
  • Noguera-Julián, Antoni
  • Fortuny, Claudia
  • Soler-Palacín, Pere
  • Espiau, María
  • Mur, Antonio
  • Coll, María T.
  • Valmanya, María T.
  • Mayol, Lluis
  • Méndez, María José
  • Rodrigo, Carlos
  • Escribano, Joaquín
  • Rius, Neus
  • Rovira, Núria
  • Calavia, Olga
  • García, Lourdes
  • Pineda, Valentí
  • Soriano-Arandes, Antoni
  • Rudin, Christoph
  • Duppenthaler, Andrea
  • Judd, Ali
  • Malyuta, Ruslan
  • Volokha, Alla
  • Raus, Irina
  • Kaleeva, T.
  • Baryshnikova, Y.
  • Soloha, Svetlana
  • Bashkatova, N.
  • Glutshenko, O.
  • Ruban, Z.
  • Primak, Natalia
  • Kiseleva, Galina
[Objective] To characterize children, adolescents and young adults infected with HIV/hepatitis C virus (HCV) vertically or before age of 18 years and living in Europe regarding mode of acquisition, HCV genotype, clinical status and treatment., [Design] Retrospective, cross-sectional study using pooled data from 11 European paediatric HIV cohorts., [Methods] Patients aged more than 18 months and less than 25 years, with HIV/HCV acquired vertically or in childhood, were included. Anonymized individual patient data were collected using a standard protocol and modified HIV Cohorts Data Exchange Protocol., [Results] Of 229 patients included, 142 (62%) had vertically acquired infection. Median age at last follow-up was 16.2 years. Most children had HCV genotype 1 (101/184, 55%) or 3 (57/184, 31%). One-fifth (46/214) had a previous AIDS diagnosis (data missing on prior AIDS diagnoses for 15). At their last clinic visit, 70% (145/208) had no/mild immunosuppression (Centers for Disease Control and Prevention stage 1), and 131 of 179 on antiretroviral therapy had undetectable HIV RNA (assay thresholds varied from <20 to <150 copies/ml). Overall, 42% (86/204) had hepatomegaly in the previous year, and 55% (116/213) had alanine aminotransferase more than 40 IU/l at their last test. Of 97 patients with transient elastography, 12 had results more than 9 kPa; this was associated with duration of HCV infection (P = 0.033), but not with CD4+ cell count, antiretroviral therapy use or sex in univariable analysis. Of 17 patients with liver biopsies, six had bridging fibrosis and one had cirrhosis. Twenty-five (11%) had been treated successfully for HCV., [Conclusion] The high proportion of patients with progressive liver disease underscores the need for close monitoring and earlier and more effective HCV treatment., This work was supported by funding from the EU Seventh Framework Programme (FP7/2007–2013) under EuroCoord grant agreement [no. 260694] and additional funding from Janssen., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study

  • Reekie, Joanne
  • Kowalska, Justyna D.
  • Karpov, Igor
  • Rockstroh, Jürgen Kurt
  • Karlsson, Anders
  • Rakhmanova, Aza
  • Horban, Andrzej
  • Kirk, Ole
  • Lundgren, Jens D.
  • Mocroft, Amanda
  • Gatell, José M.
  • Miró Meda, José M. (José María), 1956-
  • EuroSIDA Study Group
Background: Differences in access to care and treatment have been reported in Eastern Europe, a region with one of the fastest growing HIV epidemics, compared to the rest of Europe. This analysis aimed to establish whether there are regional differences in the mortality rate of HIV-positive individuals across Europe, and Argentina. Methods: 13,310 individuals under follow-up were included in the analysis. Poisson regression investigated factors associated with the risk of death. Findings: During 82,212 person years of follow-up (PYFU) 1,147 individuals died (mortality rate 14.0 per 1,000 PYFU (95% confidence interval [CI] 13.1-14.8). Significant differences between regions were seen in the rate of all-cause, AIDS and nonAIDS related mortality (global p,0.0001 for all three endpoints). Compared to South Europe, after adjusting for baseline demographics, laboratory measurements and treatment, a higher rate of AIDS related mortality was observed in East Europe (IRR 2.90, 95%CI 1.97-4.28, p,.0001), and a higher rate of non-AIDS related mortality in North Europe (IRR 1.51, 95%CI 1.24- 1.82, p,.0001). The differences observed in North Europe decreased over calendar-time, in 2009-2011, the higher rate of non-AIDS related mortality was no longer significantly different to South Europe (IRR 1.07, 95%CI 0.66-1.75, p = 0.77). However, in 2009-2011, there remained a higher rate of AIDS-related mortality (IRR 2.41, 95%CI 1.11-5.25, p = 0.02) in East Europe compared to South Europe in adjusted analysis. Interpretations: There are significant differences in the rate of all-cause mortality among HIV-positive individuals across different regions of Europe and Argentina. Individuals in Eastern Europe had an increased risk of mortality from AIDS related causes and individuals in North Europe had the highest rate of non-AIDS related mortality. These findings are important for understanding and reviewing HIV treatment strategies and policies across the European region.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mortality according to CD4 count at start of combination antiretroviral therapy among HIV-infected patients followed for up to 15 years after start of treatment: collaborative cohort study

  • May, Margaret T.
  • Vehreschild, Jörg Janne
  • Trickey, Adam
  • Obel, Niels
  • Reiss, Peter
  • Bonnet, Fabrice
  • Mary-Krause, Murielle
  • Samji, Hasina
  • Cavassini, Matthias
  • Gill, Michael John
  • Shepherd, Leah C.
  • Crane, Heidi M.
  • D'Arminio Monforte, Antonella
  • Burkholder, Greer A.
  • Johnson, Margaret M.
  • Sobrino Vegas, Paz
  • Domingo, Pere (Domingo Pedrol)
  • Zangerle, Robert
  • Justice, Amy C.
  • Sterling, Timothy R.
  • Miró Meda, José M. (José María), 1956-
  • Sterne, Jonathan A. C.
BACKGROUND: CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized. METHODS: We estimated mortality rates (MRs) by time since start of ART (<0.5, 0.5-0.9, 1-2.9, 3-4.9, 5-9.9, and ≥10 years) among patients from 18 European and North American cohorts who started ART during 1996-2001. Piecewise exponential models stratified by cohort were used to estimate crude and adjusted (for sex, age, transmission risk, period of starting ART [1996-1997, 1998-1999, 2000-2001], and AIDS and human immunodeficiency virus type 1 RNA at baseline) mortality rate ratios (MRRs) by CD4 count at start of ART (0-49, 50-99, 100-199, 200-349, 350-499, ≥500 cells/µL) overall and separately according to time since start of ART. RESULTS: A total of 6344 of 37 496 patients died during 359 219 years of follow-up. The MR per 1000 person-years was 32.8 (95% confidence interval [CI], 30.2-35.5) during the first 6 months, declining to 16.0 (95% CI, 15.4-16.8) during 5-9.9 years and 14.2 (95% CI, 13.3-15.1) after 10 years' duration of ART. During the first year of ART, there was a strong inverse association of CD4 count at start of ART with mortality. This diminished over the next 4 years. The adjusted MRR per CD4 group was 0.97 (95% CI, .94-1.00; P = .054) and 1.02 (95% CI, .98-1.07; P = .32) among patients followed for 5-9.9 and ≥10 years, respectively. CONCLUSIONS: After surviving 5 years of ART, the mortality of patients who started ART with low baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 counts.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CD4 cell count and the risk of AIDS or death in HIV infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE

  • Miró Meda, José M. (José María), 1956-
  • Noguera Julian, Antoni
  • Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
BACKGROUND: Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load. METHODS AND FINDINGS: Using data from the Collaboration of Observational HIV Epidemiological Research Europe (2010 merger), we assessed the risk of a new AIDS-defining event or death in successfully treated patients. We accumulated episodes of viral suppression for each patient while on cART, each episode beginning with the second of two consecutive plasma viral load measurements <50 copies/µl and ending with either a measurement >500 copies/µl, the first of two consecutive measurements between 50-500 copies/µl, cART interruption or administrative censoring. We used stratified multivariate Cox models to estimate the association between time updated CD4 cell count and a new AIDS event or death or death alone. 75,336 patients contributed 104,265 suppression episodes and were suppressed while on cART for a median 2.7 years. The mortality rate was 4.8 per 1,000 years of viral suppression. A higher CD4 cell count was always associated with a reduced risk of a new AIDS event or death; with a hazard ratio per 100 cells/µl (95% CI) of: 0.35 (0.30-0.40) for counts <200 cells/µl, 0.81 (0.71-0.92) for counts 200 to <350 cells/µl, 0.74 (0.66-0.83) for counts 350 to <500 cells/µl, and 0.96 (0.92-0.99) for counts ≥500 cells/µl. A higher CD4 cell count became even more beneficial over time for patients with CD4 cell counts <200 cells/µl. CONCLUSIONS: Despite the low mortality rate, the risk of a new AIDS event or death follows a CD4 cell count gradient in patients with viral suppression. A higher CD4 cell count was associated with the greatest benefit for patients with a CD4 cell count <200 cells/µl but still some slight benefit for those with a CD4 cell count ≥500 cells/µl.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.

  • Wyss, Natascha
  • Zwahlen, Marcel
  • Clifford, Gary
  • Campbell, Maria
  • Chakraborty, Rana
  • Bonnet, Fabrice
  • Chene, Geneviève
  • Bani-Sadr, Firouze
  • Verbon, Annelies
  • Zangerle, Robert
  • Paparizos, Vassilios
  • Prins, Maria
  • Dronda, Fernando
  • Le Moing, Vincent
  • Antinori, Andrea
  • Quiros Roldan, Eugenia
  • Mussini, Cristina
  • Miró Meda, José M. (José María), 1956-
  • Meyer, Laurence
  • Vehreschild, Jörg Janne
  • Obel, Niels
  • Mocroft, Amanda
  • Brockmeyer, Norbert H.
  • Boue, François
  • Sabin, Caroline
  • Spagnuolo, Vincenzo
  • Hasse, Barbara
  • Wit, Stéphane de
  • Roca, Bernardino
  • Egger, Matthias
  • Bohlius, Julia
BACKGROUND:  Kaposi sarcoma (KS) remains a frequent cancer in human immunodeficiency virus (HIV)-positive patients starting combination antiretroviral therapy (cART). We examined incidence rates and risk factors for developing KS in different periods after starting cART in patients from European observational HIV cohorts. METHODS:  We included HIV-positive adults starting cART after 1 January 1996. We analyzed incidence rates and risk factors for developing KS up to 90 and 180 days and 1, 2, 5, and 8 years after cART start and fitted univariable and multivariable Cox regression models. RESULTS:  We included 109 461 patients from 21 prospective clinical cohorts in Europe with 916 incident KS cases. The incidence rate per 100 000 person-years was highest 6 months after starting cART, at 953 (95% confidence interval, 866-1048), declining to 82 (68-100) after 5-8 years. In multivariable analyses adjusted for exposure group, origin, age, type of first-line regimen, and calendar year, low current CD4 cell counts increased the risk of developing KS throughout all observation periods after cART initiation. Lack of viral control was not associated with the hazard of developing KS in the first year after cART initiation, but was over time since starting cART increasingly positively associated (P < .001 for interaction). CONCLUSION:  In patients initiating cART, both incidence and risk factors for KS change with time since starting cART. Whereas soon after starting cART low CD4 cell count is the dominant risk factor, detectable HIV-1 RNA viral load becomes an increasingly important risk factor in patients who started cART several years earlier, independently of immunodeficiency.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

  • Caro Vega, Yanink
  • Schultze, Anna
  • Efsen, Anne Marie W.
  • Post, Frank A.
  • Panteleev, Alexander
  • Skrahin, Aliaksandr
  • Miró Meda, José M. (José María), 1956-
  • Girardi, Enrico
  • Podlekareva, Daria N.
  • Lundgren, Jens D.
  • Sierra Madero, Juan
  • Toibaro, Javier
  • Andrade Villanueva, Jaime
  • Tetradov, Simona
  • Fehr, Jan
  • Caylà i Buqueras, Joan A.
  • Losso, Marcelo H.
  • Miller, Robert F.
  • Mocroft, Amanda
  • Kirk, Ole
  • Crabtree Ramírez, Brenda
Background: Efavirenz-based antiretroviral therapy (ART) regimens are preferred for treatment of adult HIV-positive patients co-infected with tuberculosis (HIV/TB). Few studies have compared outcomes among HIV/TB patients treated with efavirenz or non-efavirenz containing regimens. Methods: HIV-positive patients aged ≥16 years with a diagnosis of tuberculosis recruited to the TB:HIV study between Jan 1, 2011, and Dec 31, 2013 in 19 countries in Eastern Europe (EE), Western Europe (WE), and Latin America (LA) who received ART concomitantly with TB treatment were included. Patients either received efavirenz-containing ART starting between 15 days prior to, during, or within 90 days after starting tuberculosis treatment, (efavirenz group), or other ART regimens (non-efavirenz group). Patients who started ART more than 90 days after initiation of TB treatment, or who experienced ART interruption of more than 15 days during TB treatment were excluded. We describe rates and factors associated with death, virological suppression, and loss to follow up at 12 months using univariate, multivariate Cox, and marginal structural models to compare the two groups of patients. Results: Of 965 patients (647 receiving efavirenz-containing ART, and 318 a non-efavirenz regimen) 50% were from EE, 28% from WE, and 22% from LA. Among those not receiving efavirenz-containing ART, regimens mainly contained a ritonavir-boosted protease inhibitor (57%), or raltegravir (22%). At 12 months 1.4% of patients in WE had died, compared to 20% in EE: rates of virological suppression ranged from 21% in EE to 61% in WE. After adjusting for potential confounders, rates of death (adjusted Hazard Ratio; aHR, 95%CI: 1.13, 0.72-1.78), virological suppression (aHR, 95%CI: 0.97, 0.76-1.22), and loss to follow up (aHR, 95%CI: 1.17, 0.81-1.67), were similar in patients treated with efavirenz and non-efavirenz containing ART regimens. Conclusion: In this large, prospective cohort, the response to ART varied significantly across geographical regions, whereas the ART regimen (efavirenz or non-efavirenz containing) did not impact on the proportion of patients who were virologically-suppressed, lost to follow up or dead at 12 months.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study

  • Judd, Ali
  • Chappell, Elizabeth
  • Turkova, Anna
  • Le Coeur, Sophie
  • Noguera Julian, Antoni
  • Goetghebuer, Tessa
  • Doerholt, Katja
  • Galli, Luisa
  • Pajkrt, Dasja
  • Marques, Laura
  • Collins, Intira J.
  • Gibb, Diana M.
  • González Tomé, Maria Isabel
  • Navarro, Marisa
  • Warszawski, Josiane
  • Königs, Christoph
  • Spoulou, Vana
  • Prata, Filipa
  • Chiappini, Elena
  • Naver, Lars
  • Giaquinto, Carlo
  • Thorne, Claire
  • Marczynska, Magdalena
  • Okhonskaia, Liubov
  • Posfay-Barbe, Klara
  • Ounchanum, Pradthana
  • Techakunakorn, Pornchai
  • Kiseleva, Galina
  • Malyuta, Ruslan
  • Volokha, Alla
  • Ene, Luminita
  • Goodall, Ruth
Background: Published estimates of mortality and progression to AIDS as children with HIV approach adulthood are limited. We describe rates and risk factors for death and AIDS-defining events in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17 middle- and high-income countries, including some in Western and Central Europe (W&CE), Eastern Europe (Russia and Ukraine), and Thailand. Methods and findings: Children with perinatal HIV aged <18 years initiating cART were followed until their 21st birthday, transfer to adult care, death, loss to follow-up, or last visit up until 31 December 2013. Rates of death and first AIDS-defining events were calculated. Baseline and time-updated risk factors for early/late (≤/>6 months of cART) death and progression to AIDS were assessed. Of 3,526 children included, 32% were from the United Kingdom or Ireland, 30% from elsewhere in W&CE, 18% from Russia or Ukraine, and 20% from Thailand. At cART initiation, median age was 5.2 (IQR 1.4-9.3) years; 35% of children aged <5 years had a CD4 lymphocyte percentage <15% in 1997-2003, which fell to 15% of children in 2011 onwards (p < 0.001). Similarly, 53% and 18% of children ≥5 years had a CD4 count <200 cells/mm3 in 1997-2003 and in 2011 onwards, respectively (p < 0.001). Median follow-up was 5.6 (2.9-8.7) years. Of 94 deaths and 237 first AIDS-defining events, 43 (46%) and 100 (42%) were within 6 months of initiating cART, respectively. Multivariable predictors of early death were: being in the first year of life; residence in Russia, Ukraine, or Thailand; AIDS at cART start; initiating cART on a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen; severe immune suppression; and low BMI-for-age z-score. Current severe immune suppression, low current BMI-for-age z-score, and current viral load >400 c/mL predicted late death. Predictors of early and late progression to AIDS were similar. Study limitations include incomplete recording of US Centers for Disease Control (CDC) disease stage B events and serious adverse events in some countries; events that were distributed over a long time period, and that we lacked power to analyse trends in patterns and causes of death over time. Conclusions: In our study, 3,526 children and adolescents with perinatal HIV infection initiated antiretroviral therapy (ART) in countries in Europe and Thailand. We observed that over 40% of deaths occurred ≤6 months after cART initiation. Greater early mortality risk in infants, as compared to older children, and in Russia, Ukraine, or Thailand as compared to W&CE, raises concern. Current severe immune suppression, being underweight, and unsuppressed viral load were associated with a higher risk of death at >6 months after initiation of cART.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

  • Zoufaly, Alexander
  • Cozzi-Lepri, Alessandro
  • Reekie, Joanne
  • Kirk, Ole
  • Lundgren, Jens D.
  • Reiss, Peter
  • Jevtovic, Djordje
  • Machala, Ladislav
  • Zangerle, Robert
  • Mocroft, Amanda
  • Van Lunzen, Jan 1963-
  • Miró Meda, José M. (José María), 1956-
  • Gatell, José M.
The impact of immunosuppression despite virological suppression (immuno-virological discordance, ID) on the risk of developing fatal and non-fatal AIDS/non-AIDS events is unclear and remains to be elucidated. METHODS: Patients in EuroSIDA starting at least 1 new antiretroviral drug with CD4<350 cells/µl and viral load (VL)>500 copies/mL were followed-up from the first day of VL< = 50 copies/ml until a new fatal/non-fatal non-AIDS/AIDS event. Considered non-AIDS events included non-AIDS malignancies, pancreatitis, severe liver disease with hepatic encephalopathy (>grade 3), cardio- and cerebrovascular events, and end-stage renal disease. Patients were classified over time according to whether current CD4 count was above (non-ID) or below (ID) baseline level. Relative rates (RR) of events were calculated for ID vs. non-ID using adjusted Poisson regression models. RESULTS: 2,913 patients contributed 11,491 person-years for the analysis of non-AIDS. 241 pre-specified non-AIDS events (including 84 deaths) and 89 AIDS events (including 10 deaths) occurred. The RR of developing pre-specified non-AIDS events for ID vs. non-ID was 1.96 (95% CI 1.37-2.81, p<0.001) in unadjusted analysis and 1.43 (0.94-2.17, p = 0.095) after controlling for current CD4 count. ID was not associated with the risk of AIDS events (aRR 0.76, 95% CI 0.41-1.38, p = 0.361). CONCLUSION: Compared to CD4 responders, patients with immuno-virological discordance may be at increased risk of developing non-AIDS events. Further studies are warranted to establish whether in patients with ID, strategies to directly modify CD4 count response may be needed besides the use of ART.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB: HIV study

  • Efsen, Anne Marie W.
  • Schultze, Anna
  • Miller, Robert F.
  • Panteleev, Alexander
  • Skrahin, Aliaksandr
  • Podlekareva, Daria N.
  • Miró Meda, José M. (José María), 1956-
  • Girardi, Enrico
  • Furrer, Hansjakob
  • Losso, Marcelo H.
  • Toibaro, Javier
  • Caylà i Buqueras, Joan A.
  • Mocroft, Amanda
  • Lundgren, Jens D.
  • Kirk, Ole
  • Post, Frank A.
  • Manzardo, Christian
  • Ligero, M. C.
  • González, J.
  • HIV study in EuroCoord
Objectives: Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods: In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART). Results: A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5-74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%. Conclusions: Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

  • Pantazis, Nikos
  • Morrison, Charles
  • Amornkul, Pauli N.
  • Lewden,Charlotte
  • Salata, Robert A
  • Minga, Albert
  • Chipato, Tsungai
  • Jaffe, Harold
  • Lakhi, Shabir
  • Karita, Etienne
  • Porter, Kholoud
  • Meyer, Laurence
  • Touloumi, Giota
  • CASCADE Collaboration in EuroCoord
  • ANRS 1220 Primo-CI Study Group.
  • Gatell, José M.
Introduction: It is unknown whether HIV treatment guidelines, based on resource-rich country cohorts, are applicable to African populations. Methods: We estimated CD4 cell loss in ART-naïve, AIDS-free individuals using mixed models allowing for random intercept and slope, and time from seroconversion to clinical AIDS, death and antiretroviral therapy (ART) initiation by survival methods. Using CASCADE data from 20 European and 3 sub-Saharan African (SSA) cohorts of heterosexually-infected individuals, aged ≥15 years, infected ≥2000, we compared estimates between non-African Europeans, Africans in Europe, and Africans in SSA. Results: Of 1,959 (913 non-Africans, 302 Europeans - African origin, 744 SSA), two-thirds were female; median age at seroconversion was 31 years. Individuals in SSA progressed faster to clinical AIDS but not to death or non-TB AIDS. They also initiated ART later than Europeans and at lower CD4 cell counts. In adjusted models, Africans (especially from Europe) had lower CD4 counts at seroconversion and slower CD4 decline than non-African Europeans. Median (95% CI) CD4 count at seroconversion for a 15-29 year old woman was 607 (588-627) (non-African European), 469 (442-497) (European - African origin) and 570 (551-589) (SSA) cells/µL with respective CD4 decline during the first 4 years of 259 (228-289), 155 (110-200), and 199 (174-224) cells/µL (p<0.01). Discussion: Despite differences in CD4 cell count evolution, death and non-TB AIDS rates were similar across study groups. It is therefore prudent to apply current ART guidelines from resource-rich countries to African populations.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation

  • Pettit, April C.
  • Giganti, Mark J.
  • Ingle, Suzanne M.
  • May, Margaret T.
  • Shepherd, Bryan E.
  • Gill, Michael John
  • Fätkenheuer, Gerd
  • Abgrall, Sophie
  • Saag, Michael S.
  • Amo Valero, Julia del
  • Justice, Amy C.
  • Miró Meda, José M. (José María), 1956-
  • Cavassini, Matthias
  • Dabis, François
  • Monforte, Antonella D.
  • Reiss, Peter
  • Guest, Jodie
  • Moore, David
  • Shepherd, Leah C.
  • Obel, Niels
  • Crane, Heidi M.
  • Smith, Colette J.
  • Zangerle, Robert
  • Sterne, Jonathan A. C.
  • Sterling, Timothy R.
  • Teira, Ramon
  • Antiretroviral Therapy Cohort Collaboration
Introduction:HIV-1 infection leads to chronic inflammation and to an increased risk of non-AIDS mortality. Our objective wasto determine whether AIDS-defining events (ADEs) were associated with increased overall and cause-specific non-AIDSrelated mortality after antiretroviral therapy (ART) initiation.Methods:We included HIV treatment-na ıve adults from the Antiretroviral Therapy Cohort Collaboration (ART-CC) who initi-ated ART from 1996 to 2014. Causes of death were assigned using the Coding Causes of Death in HIV (CoDe) protocol. Theadjusted hazard ratio (aHR) for overall and cause-specific non-AIDS mortality among those with an ADE (all ADEs, tuberculosis(TB),Pneumocystis jirovecipneumonia (PJP), and non-Hodgkin's lymphoma (NHL)) compared to those without an ADE was esti-mated using a marginal structural model.Results:The adjusted hazard of overall non-AIDS mortality was higher among those with any ADE compared to thosewithout any ADE (aHR 2.21, 95% confidence interval (CI) 2.00 to 2.43). The adjusted hazard of each of the cause-specificnon-AIDS related deaths were higher among those with anyADE compared to those without, except metabolic deaths(malignancy aHR 2.59 (95% CI 2.13 to 3.14), accident/suicide/overdose aHR 1.37(95% CI 1.05 to 1.79), cardiovascularaHR 1.95 (95% CI 1.54 to 2.48), infection aHR (95% CI 1.68 to 2.81), hepatic aHR 2.09 (95% CI 1.61 to 2.72), respira-tory aHR 4.28 (95% CI 2.67 to 6.88), renal aHR 5.81 (95% CI 2.69 to 12.56) and central nervous aHR 1.53 (95% CI 1.18to 5.44)). The risk of overall and cause-specific non-AIDS mortality differed depending onthe specific ADE of interest(TB, PJP, NHL).Conclusions:In this large multi-centre cohort collaboration with standardized assignment of causes of death, non-AIDS mor-tality was twice as high among patients with an ADE compared to without an ADE. However, non-AIDS related mortality afteran ADE depended on the ADE of interest. Although there may be unmeasured confounders, these findings suggest that acommon pathway may be independently driving both ADEs and NADE mortality. While prevention of ADEs may reduce subse-quent death due to NADEs following ART initiation, modification of risk factors for NADE mortality remains important afterADE survival.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

  • Mocroft, Amanda
  • Lundgren, Jens D.
  • Sabin, Miriam Lewis
  • Arminio Monforte, Antonella d'
  • Brockmeyer, Norbert H.
  • Casabona, Jordi
  • Castagna, Antonella
  • Costagliola, Dominique
  • Dabis, François
  • De Wit, Stéphane
  • Fätkenheuer, Gerd
  • Furrer, Hansjakob
  • Johnson, Anne M.
  • Lazanas, Marios K.
  • Leport, Catherine
  • Moreno, Santiago
  • Obel, Niels
  • Post, Frank A.
  • Reekie, Joanne
  • Reiss, Peter
  • Sabin, Caroline
  • Skaletz Rorowski, Adriane
  • Suarez Lozano, Ignacio
  • Torti, Carlo
  • Warszawski, Josiane
  • Zangerle, Robert
  • Fabre Colin, Céline
  • Kjaer, Jesper
  • Chene, Geneviève
  • Grarup, Jesper
  • Kirk, Ole
  • Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
Background: Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. Methods and Findings: LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm3 or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). Conclusions: LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Premature aging and immune senescence in HIV-infected children.

  • Gianesin, Ketty
  • Noguera Julian, Antoni
  • Zanchetta, Marisa
  • Del Bianco, Paola
  • Petrara, Maria Raffaella
  • Freguja, Riccardo
  • Rampon, Osvalda
  • Fortuny Guasch, Claudia
  • Camós Guijosa, Mireia
  • Mozzo, Elena
  • Giaquinto, Carlo
  • De Rossi, Anita
Objective: Several pieces of evidence indicate that HIV-infected adults undergo premature aging. The effect of HIV and antiretroviral therapy (ART) exposure on the aging process of HIV-infected children may be more deleterious since their immune system coevolves from birth with HIV. Design: Seventy-one HIV-infected (HIV+), 65 HIV-exposed-uninfected (HEU), and 56 HIV-unexposed-uninfected (HUU) children, all aged 0-5 years, were studied for biological aging and immune senescence. Methods: Telomere length and T-cell receptor rearrangement excision circle levels were quantified in peripheral blood cells by real-time PCR. CD4+ and CD8+ cells were analysed for differentiation, senescence, and activation/exhaustion markers by flow cytometry. Results: Telomere lengths were significantly shorter in HIV+ than in HEU and HUU children (overall, P < 0.001 adjusted for age); HIV+ ART-naive (42%) children had shorter telomere length compared with children on ART (P = 0.003 adjusted for age). T-cell receptor rearrangement excision circle levels and CD8+ recent thymic emigrant cells (CD45RA+CD31+) were significantly lower in the HIV+ than in control groups (overall, P = 0.025 and P = 0.005, respectively). Percentages of senescent (CD28−CD57+), activated (CD38+HLA-DR+), and exhausted (PD1+) CD8+ cells were significantly higher in HIV+ than in HEU and HUU children (P = 0.004, P < 0.001, and P < 0.001, respectively). Within the CD4+ cell subset, the percentage of senescent cells did not differ between HIV+ and controls, but programmed cell death receptor-1 expression was upregulated in the former. Conclusions: HIV-infected children exhibit premature biological aging with accelerated immune senescence, which particularly affects the CD8+ cell subset. HIV infection per se seems to influence the aging process, rather than exposure to ART for prophylaxis or treatment. Keywords: immune activation, immune senescence, microbial translocation, pediatric HIV/AIDS, premature aging, telomere length, T-cell receptor rearrangement excision circle
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

  • Peters, Lars
  • Mocroft, Amanda
  • Soriano, Vincent
  • Rockstroh, Jürgen Kurt
  • Rauch, Andri
  • Karlsson, Anders
  • Knysz, Brygida
  • Pradier, Christian
  • Zilmer, Kai
  • Lundgren, Jens D.
  • Gatell, José M.
  • Miró Meda, José M. (José María), 1956-
  • EuroSIDA Study Group
Background: Whereas it is well established that various soluble biomarkers can predict level of liver fibrosis, their ability to predict liver-related clinical outcomes is less clearly established, in particular among HIV/viral hepatitis co-infected persons. We investigated plasma hyaluronic acid's (HA) ability to predict risk of liver-related events (LRE; hepatic coma or liver-related death) in the EuroSIDA study. Methods: Patients included were positive for anti-HCV and/or HBsAg with at least one available plasma sample. The earliest collected plasma sample was tested for HA (normal range 0-75 ng/mL) and levels were associated with risk of LRE. Change in HA per year of follow-up was estimated after measuring HA levels in latest sample before the LRE for those experiencing this outcome (cases) and in a random selection of one sixth of the remaining patients (controls). Results: During a median of 8.2 years of follow-up, 84/1252 (6.7%) patients developed a LRE. Baseline median (IQR) HA in those without and with a LRE was 31.8 (17.2-62.6) and 221.6 ng/mL (74.9-611.3), respectively (p,0.0001). After adjustment, HA levels predicted risk of contracting a LRE; incidence rate ratios for HA levels 75-250 or $250 vs. ,75 ng/mL were 5.22 (95% CI 2.86-9.26, p,0.0007) and 28.22 (95% CI 14.95-46.00, p,0.0001), respectively. Median HA levels increased substantially prior to developing a LRE (107.6 ng/mL, IQR 0.8 to 251.1), but remained stable for controls (1.0 ng/mL, IQR -5.1 to 8.2), (p,0.0001 comparing cases and controls), and greater increases predicted risk of a LRE in adjusted models (p,0.001). Conclusions: An elevated level of plasma HA, particularly if the level further increases over time, substantially increases the risk of contracting LRE over the next five years. HA is an inexpensive, standardized and non-invasive supplement to other methods aimed at identifying HIV/viral hepatitis co-infected patients at risk of hepatic complications.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration.

  • Olson, Ashley D.
  • Meyer, Laurence
  • Prins, Maria
  • Thiebaut, Rodolphe
  • Gurdasani, Deepti
  • Guiguet, Marguerite
  • Chaix, Marie-Laure
  • Amornkul, Pauli N.
  • Babiker, Abdel
  • Sandhu, Manjinder S.
  • Porter, Kholoud
  • Gatell, José M.
BACKGROUND: Understanding the mechanisms underlying viral control is highly relevant to vaccine studies and elite control (EC) of HIV infection. Although numerous definitions of EC exist, it is not clear which, if any, best identify this rare phenotype. METHODS: We assessed a number of EC definitions used in the literature using CASCADE data of 25,692 HIV seroconverters. We estimated proportions maintaining EC of total ART-naïve follow-up time, and disease progression, comparing to non-EC. We also examined HIV-RNA and CD4 values and CD4 slope during EC and beyond (while ART naïve). RESULTS: Most definitions classify ∼ 1% as ECs with median HIV-RNA 43-903 copies/ml and median CD4>500 cells/mm(3). Beyond EC status, median HIV-RNA levels remained low, although often detectable, and CD4 values high but with strong evidence of decline for all definitions. Median % ART-naïve time as EC was ≥ 92% although overlap between definitions was low. EC definitions with consecutive HIV-RNA measurements <75 copies/ml with follow-up ≥ six months, or with 90% of measurements <400 copies/ml over ≥ 10 year follow-up preformed best overall. Individuals thus defined were less likely to progress to endpoint (hazard ratios ranged from 12.5-19.0 for non-ECs compared to ECs). CONCLUSIONS: ECs are rare, less likely to progress to clinical disease, but may eventually lose control. We suggest definitions requiring individuals to have consecutive undetectable HIV-RNA measurements for ≥ six months or otherwise with >90% of measurements <400 copies/ml over ≥ 10 years be used to define this phenotype.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013-March 2014

  • Simmons, Ruth
  • Malyuta, Ruslan
  • Chentsova, Nelli
  • Medoeva, Antonia
  • Kruglov, Yuri
  • Yurchenko, Alexander
  • Copas, Andrew
  • Porter, Kholoud
Data from Ukraine on risk factors for HIV acquisition are limited. We describe the characteristics of individuals testing for HIV in the main testing centres of the Ukrainian capital Kiev, including HIV risk factors, testing rates, and positivity rates. As part of a larger study to estimate HIV incidence within Kiev City, we included questions on possible risk factors for HIV acquisition and testing history to existing systems in 4 infectious disease clinics. Data were provided by the person requesting an HIV test using a handheld electronic tablet. All persons (≥16 yrs) presenting for an HIV test April 2013-March 2014 were included. Rates per 100,000 were calculated using region-specific denominators for Kiev. During the study period 6370 individuals tested for HIV, equivalent to a testing rate of 293.2 per 100,000. Of these, 467 (7.8%) were HIV-positive, with the highest proportion positive among 31-35 year olds (11.2%), males (9.4%), people who inject drugs (PWID) (17.9%) and men who have sex with men (MSM) (24.1%). Using published population size estimates of MSM, diagnosis rates for MSM ranged from 490.6 to 1548.3/100,000. A higher proportion of heterosexual women compared to heterosexual men reported contact with PWID, (16% vs. 4.7%) suggesting a bridging in risk between PWID and their sexual partners. Collection of HIV risk factor information in Kiev, essential for the purposes of developing effective HIV prevention and response tools, is feasible. The high percentage of MSM among those testing positive for HIV, may indicate a significant level of undisclosed sex between men in national figures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype

  • Olson, Ashley D.
  • Guiguet, Marguerite
  • Zangerle, Robert
  • Gill, John
  • Pérez-Hoyos, Santiago|||0000-0001-9797-4917
  • Lodi, Sara
  • Ghosn, Jade
  • Dorrucci, Maria
  • Johnson, Anne
  • Sannes, Mette
  • Moreno, Santiago|||0000-0002-2843-1094
  • Porter, Kholoud
Supplemental Digital Content is Available in the Text. Rapid CD4 cell loss represents an HIV phenotype used to identify causal variants of accelerated disease progression. The optimal rate and threshold for identifying this extreme phenotype in recently infected individuals is unclear. Using a cohort of patients with known dates of HIV-1 seroconversion (SC), CASCADE (Concerted Action on SeroConversion on AIDS and Death in Europe), we identified proportions experiencing nadir CD4 cell levels within 1 year of SC, and assessed their mean AIDS-free survival time at 10-year follow-up and hazard of AIDS/death, compared with those whose CD4 remained.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?

  • Jarrín, Inma|||0000-0002-7485-2252
  • Pantazis, Nikos
  • Dalmau, Judith|||0000-0001-7513-3711
  • Phillips, Andrew N.
  • Olson, Ashley
  • Mussini, Cristina|||0000-0002-6615-4198
  • Boufassa, Faroudy
  • Costagliola, Dominique
  • Porter, Kholoud
  • Blanco, Julià|||0000-0002-2225-0217
  • Del Amo, Julia|||0000-0002-3104-540X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
This article compares trends in CD4 + T-cell recovery and proportions achieving optimal restoration (≥500 cells/μl) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. We included HIV-1 seroconverters achieving viral suppression within 6 months of cART. Rapid progressors were individuals experiencing at least one CD4 + less than 200 cells/μl within 12 months of seroconverters before cART. We used piecewise linear mixed models and logistic regression for optimal restoration. Of 4024 individuals, 294 (7.3%) were classified as rapid progressors. At the same CD4 + T-cell count at cART start (baseline), rapid progressors experienced faster CD4 + T-cell increases than nonrapid progressors in first month [difference (95% confidence interval) in mean increase/month (square root scale): 1.82 (1.61; 2.04)], which reversed to slightly slower increases in months 1-18 [-0.05 (-0.06; -0.03)] and no significant differences in 18-60 months [-0.003 (-0.01; 0.01)]. Percentage achieving optimal restoration was significantly lower for rapid progressors than nonrapid progressors at months 12 (29.2 vs. 62.5%) and 36 (47.1 vs. 72.4%) but not at month 60 (70.4 vs. 71.8%). These differences disappeared after adjusting for baseline CD4 + T-cell count: odds ratio (95% confidence interval) 0.86 (0.61; 1.20), 0.90 (0.38; 2.17) and 1.56 (0.55; 4.46) at months 12, 36 and 60, respectively. Among people on suppressive antiretroviral therapy, rapid progressors experience faster initial increases of CD4 + T-cell counts than nonrapid progressors, but are less likely to achieve optimal restoration during the first 36 months after cART, mainly because of lower CD4 + T-cell counts at cART initiation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma HIV-1 Tropism and the Risk of Short- Term Clinical Progression to AIDS or Death

  • Casadellà, Maria|||0000-0002-4115-2305
  • Cozzi-Lepri, Alessandro|||0000-0002-6339-919X
  • Phillips, Andrew
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Bickel, Markus
  • Sedlacek, Dalibor
  • Zilmer, Kai
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Lundgren, Jens|||0000-0001-8901-7850
  • Paredes, Roger|||0000-0002-6553-691X
Objective. To investigate if plasma HIV-1 tropism testing could identify subjects at higher risk for clinical progression and death in routine clinical management. Design. Nested case-control study within the EuroSIDA cohort. Methods. Cases were subjects with AIDS or who died from any cause, with a plasma sample with HIV-1 RNA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers

  • Chereau, Fanny
  • Madec, Yoann
  • Sabin, Caroline A.
  • Obel, Niels|||0000-0002-5031-0045
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Chrysos, Georgios
  • Fidler, Sarah|||0000-0003-1676-7583
  • Lehmann, Clara
  • Zangerle, Robert
  • Wittkop, Linda|||0000-0003-2403-0960
  • Reiss, Peter
  • Hamouda, Osamah
  • Estrada, Vicente|||0000-0002-7795-5986
  • Leal, Manuel
  • Mocroft, Amanda
  • García de Olalla, Patricia|||0000-0002-2293-3560
  • Ammassari, Adriana
  • D'Arminio Monforte, Antonella
  • Mussini, Cristina|||0000-0002-6615-4198
  • Segura, Ferran
  • Castagna, Antonella|||0000-0002-8338-9714
  • Cavassini, Matthias
  • Grabar, Sophie
  • Morlat, Philippe
  • De Wit, Stéphane
  • Lambotte, Olivier
  • Meyer, Laurence
HIV controllers (HICs) spontaneously maintain HIV viral replication at low level without antiretroviral therapy (ART), a small number of whom will eventually lose this ability to control HIV viremia. The objective was to identify factors associated with loss of virological control. HICs were identified in COHERE on the basis of ≥5 consecutive viral loads (VL) ≤500 copies/mL over ≥1 year whilst ART-naive, with the last VL ≤500 copies/mL measured ≥5 years after HIV diagnosis. Loss of virological control was defined as 2 consecutive VL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression

  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Cozzi-Lepri, Alessandro|||0000-0002-6339-919X
  • Pedersen, Court
  • Ristola, Matti
  • Losso, Marcelo
  • Mocroft, Amanda
  • Mitsura, Viktar
  • Falconer, Karolin
  • Maltez, Fernando
  • Beniowski, Marek
  • Vullo, Vincenzo
  • Hassoun, Gamal
  • Kuzovatova, Elena
  • Szlavik, János
  • Kuznetsova, Anastasiia
  • Stellbrink, Hans-Jürgen
  • Duvivier, Claudine
  • Edwards, Simon
  • Laut, Kamilla
  • Paredes, Roger|||0000-0002-6553-691X
Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR <50 copies/mL) and a snapshot analysis at 48, 96, and 144 weeks. Virological failure (VF) was defined as confirmed pVL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Observational cohort study of rilpivirine (RPV) utilization in Europe

  • Cozzi-Lepri, Alessandro|||0000-0002-6339-919X
  • Peters, Lars
  • Pelchen-Matthews, Annegret|||0000-0002-0994-5655
  • Neesgaard, Bastian
  • De Wit, Stéphane
  • Johansen, Isik Somuncu|||0000-0002-2189-9823
  • Edwards, Simon
  • Stephan, Christoph
  • Adamis, Georgios
  • Staub, Therese|||0000-0003-4898-4566
  • Zagalo, Alexandra
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Elbirt, Daniel
  • Kusejko, Katharina|||0000-0002-4638-1940
  • Brännström, Johanna|||0000-0001-7684-8591
  • Paduta, Dzmitry
  • Trofimova, Tatyana
  • Szlavik, János
  • Zilmer, Kai
  • Losso, Marcello
  • Van Eygen, Veerle
  • Pai, Helen
  • Lundgren, Jens|||0000-0001-8901-7850
  • Mocroft, Amanda
  • Harxhi, Arjan
  • Losso, Marcelo Horacio
  • Kundro, Mariana
  • Schmied, Brigitte
  • Karpov, Igor Alexandrovich
  • Vassilenko, Anna|||0000-0003-1907-2322
  • Paduto, Dmitriy
  • Mitsura, Viktar
  • Clumeck, Nathan N.
  • De Wit, Stéphane
  • Delforge, Marc D.
  • Hadziosmanovic, Vesnadarjan
  • Begovac, Josip|||0000-0003-2641-4327
  • Machala, Ladislav
  • Jilich, David
  • Gerstoft, Jan
  • Torp-Pedersen, Christian
  • Sedlacek, Dalibor
  • Kronborg, Gitte
  • Benfield, Thomas|||0000-0003-0698-9385
  • Ostergaard, Leif
  • Wiese, Lothar
  • Friis-Moller, Nina
  • Nielsen, Lars Norregård
  • Zilmer, Kai
  • Smidt, Jelena
  • Aho, Inka
  • Viard, Jean-Paul
  • Girard, Pierre-Marie
  • Pradier, Christian
  • Fontas, Eric
  • Duvivier, Claudine
  • Rockstroh, Jurgen
  • Degen, Olaf
  • Hoffmann, C.
  • Stellbrink, Hans-Jürgen
  • Stefan, C.
  • Bogner, Johannes
  • Fätkenheuer, Gerd
  • Chkhartishvili, N.
  • Sambatakou, Helen
  • Paissios, N.
  • Uzdaviniene, V.
  • Staub, T.
  • Dragas, Snezana
  • Reiss, Peter
  • Trajanovska, J.
  • Reikvam, Dag Henrik
  • Maeland, A.
  • Bruun, Johan
  • Knysz, B.
  • Szetela, Bartosz
  • Inglot, Malgorzata
  • Bakowska, E.
  • Flisiak, Robert|||0000-0003-3394-1635
  • Grzeszczuk, Anna|||0000-0002-6420-5545
  • Parczewski, Miłosz
  • Maciejewska, Katarzyna
  • Aksak-Was, Bogusz
  • Beniowski, Marek
  • Mularska, Elżbieta
  • Jablonowska, Elżbieta
  • Kamerys, J.
  • Wojcik, Kamila Malgorzata
  • Mozer-Lisewska, Iwona
  • Rozplochowski, Błażej
  • Radoi, Roxana
  • Oprea, Cris
  • Yakovlev, A.
  • Trofimora, T.
  • Khromova, I.
  • Kuzovatova, Elena
  • Borodulina, Elena
  • Vdoushkina, Elena
  • Ranin, Jovan
  • Tomazic, J.
  • Miro, Josep M.
  • Laguno Centeno, Montserrat|||0000-0002-7798-6352
  • Martínez, Esteban|||0000-0002-6911-8846
  • Garcia, F.
  • Blanco Arévalo, José Luis|||0000-0003-2010-2744
  • Martínez Rebollar, María
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Callau, Pilar
  • Rojas, J.
  • Moreno, Santiago|||0000-0002-2843-1094
  • del Campo, Santos|||0000-0003-2234-5432
  • Jou, Antoni|||0000-0003-2389-7618
  • Paredes, Roger|||0000-0002-6553-691X
  • Puig, Jordi|||0000-0002-4075-0346
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Santos, J.R.
  • Gutierrez, M.
  • Mateo, G.M.
  • Sambeat, A.
  • Laporte, J.M.
  • Svedhem, V.
  • Thalme, Anders
  • Sonnerborg, A.
  • Flamholc, L.
  • Kusejko, Katharina|||0000-0002-4638-1940
  • Weber, R.
  • Calmy, Alexandra|||0000-0002-1137-6826
  • Furrer, Hansjakob
  • Battegay, Manuel
  • Schmid, P.
  • Kuznetsova, A.
  • Mikhalik, Julia
  • Sluzhynska, M.
  • Milinkovic, Ana
  • Johnson, A.M.
  • Simons, Edwards
  • Edwards, S.
  • Phillips, A.M.
  • Johnson, M.A.
  • Mocroft, Amanda
  • Orkin, Chloe|||0000-0001-6168-6745
  • Winston, Alan
  • Clarke, A.
  • Leen, Clifford|||0000-0001-8439-7719
Introduction: Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce. Methods: Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann-Whitney U test and Chi-square test. A logistic regression model was used to compare participants' characteristics by treatment group. Kaplan-Meier analysis was used to estimate the cumulative risk of virological failure (VF, two consecutive values.